{
    "clinical_study": {
        "@rank": "16817", 
        "arm_group": [
            {
                "arm_group_label": "Test Product Formula A", 
                "arm_group_type": "Experimental", 
                "description": "Metronidazole benzoate"
            }, 
            {
                "arm_group_label": "Reference Product Formula B", 
                "arm_group_type": "Active Comparator", 
                "description": "Flagyl 125 mg/5 ml oral suspension"
            }, 
            {
                "arm_group_label": "Reference Product Formula C", 
                "arm_group_type": "Active Comparator", 
                "description": "Flagyl 400 mg Tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Terix Labs Ltd Metronidazole benzoate (400\n      mg Metronidazole Per Sachet Oral Granules) is bioequivalent to 500 mg Sanofi-aventis Flagyl\n      125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension) and to Zentiva Flagyl\u2122 400 mg Tablets\n      (400 mg Metronidazole Per Film Coated Tablets)."
        }, 
        "brief_title": "Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Bacterial Infections", 
        "condition_browse": {
            "mesh_term": "Bacterial Infections"
        }, 
        "detailed_description": {
            "textblock": "This study is a pilot study exploited for exploratory purposes to compare the absorption and\n      disposition kinetics of three products containing metronidazole under fasting conditions.\n      These products are: Metronidazole benzoate (formula A), Test product manufactured by ONE\n      PHARMA, Greece. Flagyl 125 mg/5 ml (formula B), a Reference product manufactured by Unither\n      Liquid Manufacturing, France and Flagyl\u2122 400 mg Tablets (formula C), a Reference product\n      manufactured by Famar Health Care Services, Spain. The bioequivalence of a single 400 mg\n      dose of products A and C, and a single 500 mg dose of product B will be assessed by\n      comparing the pharmacokinetic parameters derived from the plasma concentration-time profiles\n      for metronidazole."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 50 years, inclusive.\n\n          -  Body Mass Index (BMI) range is within 18.5 - 30 Kg/m2.\n\n          -  Subject does not have a known allergy to the drug under investigation or any of its\n             ingredients or any other related drugs.\n\n        Exclusion Criteria:\n\n          -  Medical demographics performed not longer than two weeks before the initiation of the\n             clinical study with significant deviations from the normal ranges.\n\n          -  Results of laboratory tests are within the normal range except for Hb and RBC indices\n             test that should be within the 5% of reference range and kidney function tests\n             (Creatinine will be accepted if below reference range) that are outside the reference\n             range. (Laboratory tests are performed not longer than two weeks before the\n             initiation of the clinical study).\n\n          -  Acute infection within one week preceding first study drug administration.\n\n          -  History of drug or alcohol abuse.\n\n          -  Subject is a heavy smoker (more than 10 cigarettes per day).\n\n          -  Subject does not agree not to take any prescription or non-prescription drugs within\n             the two weeks preceding the first study drug administration until donating the last\n             sample of the study.\n\n          -  Subject does not agree not to take any vitamins taken for nutritional purposes within\n             two days before first study drug administration until donating the last sample of the\n             study.\n\n          -  Subject is on a special diet (for example subject is a vegetarian).\n\n          -  Subject consumes large quantities of alcohol or beverages containing methylxanthines\n             e.g. caffeine (coffee, tea, cola, chocolate etc).\n\n          -  Subject does not agree not to consume any beverages or food containing alcohol 48\n             hours prior to study drug administration until donating the last sample in each\n             respective period.\n\n          -  Subject does not agree not to consume any beverages or food containing\n             methyl-xanthines e.g. caffeine (coffee, tea, cola, chocolate etc.) 24 hours prior to\n             the study drug administration until the end of confinement period.\n\n          -  Subject does not agree not to consume any beverages or food containing grapefruit 7\n             days prior to first study drug administration until donating the last sample in the\n             study.\n\n          -  Subject has a history of severe diseases which have direct impact on the study.\n\n          -  Participation in a bioequivalence study or in a clinical study within the last 80\n             days before first study drug administration.\n\n          -  Subject intends to be hospitalized within 3 months after first study drugs\n             administration.\n\n          -  Subjects who donated blood or its derivatives in the past 3 months or who through\n             completion of this study, would have donated more than 1250 ml in 120 days, 1500 ml\n             in 180 days, 2000 ml in 270 days, 2500 ml of blood in 1 year.\n\n          -  Subject has a history of significant asthma, peptic or gastric ulcer, sinusitis,\n             pharyngitis, renal disorder (impaired renal function), hepatic disorder (impaired\n             hepatic function), cardiovascular disorder, neurological disease such as epilepsy,\n             haematological disorders or diabetes, psychiatric, dermatologic or immunological\n             disorders.\n\n          -  Subject who have been engaged in strenuous exercise at least one day prior to dosing\n             till the last sample of each respective period.\n\n          -  Subject having at screening examination a pulse outside the normal range of (60-100\n             beat per minute) or a body temperature outside the normal range of (36.4-37.7 \u25cbC) or\n             a respiratory rate outside the normal range of (14-20 breath per minute) or a sitting\n             blood pressure less than 100/60 mm Hg or more than or equal to 140/90 mm Hg.\n\n          -  Subject has history of difficulties in swallowing or any gastrointestinal disease\n             which could affect the drug absorption."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146209", 
            "org_study_id": "MET-GST006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test Product Formula A", 
                "description": "Single oral dose of 400 mg", 
                "intervention_name": "Metronidazole benzoate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Product Formula B", 
                "description": "Single oral dose of 500 mg (20 ml suspension)", 
                "intervention_name": "Flagyl 125 mg/5 ml oral suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Reference Product Formula C", 
                "description": "Single oral dose of 400 mg", 
                "intervention_name": "Flagyl 400 mg Tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Benzoates", 
                "Metronidazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Amman", 
                    "country": "Jordan", 
                    "zip": "963166"
                }, 
                "name": "International Pharmaceutical Research Center (IPRC)"
            }, 
            "investigator": {
                "last_name": "Abdullah Hiyari, Medicine", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Jordan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparative Randomized, Single Dose, Three-Period Crossover Open-Label Study to Determine the Bioequivalence Of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules (Formula A)) Relative to 500 mg From Sanofi-aventis Flagyl 125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension (Formula B)) and Zentiva Flagyl\u2122 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablets (Formula C)) , After an Oral Administration to Healthy Adults Under Fasting Conditions", 
        "overall_contact": {
            "email": "h.zqqout@iprc.com.jo", 
            "last_name": "Halah Zaqqout, B.Sc. Pharm", 
            "phone": "+962-6-562-7651/2", 
            "phone_ext": "116"
        }, 
        "overall_official": [
            {
                "affiliation": "IPRC Jordan", 
                "last_name": "Naji Najib, B.Sc. Pharm", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "IPRC Jordan", 
                "last_name": "Abdullah Hiyari, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Jordan: Jordanian Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The area under the plasma concentration versus time curve", 
            "measure": "Plasma concentration time profiles under the curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "0, 15, 30 and 45 minutes and 1.00, 1.33, 1.67, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146209"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum measured plasma concentration", 
                "measure": "Maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 15, 30 and 45 minutes and 1.00, 1.33, 1.67, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose"
            }, 
            {
                "description": "Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value", 
                "measure": "Time to maximum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 15, 30 and 45 minutes and 1.00, 1.33, 1.67, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose"
            }, 
            {
                "description": "Apparent first-order elimination or terminal rate constant", 
                "measure": "Elimination rate constant (Kel)", 
                "safety_issue": "No", 
                "time_frame": "0, 15, 30 and 45 minutes and 1.00, 1.33, 1.67, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose"
            }, 
            {
                "description": "The elimination or terminal half-life", 
                "measure": "Terminal half life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0, 15, 30 and 45 minutes and 1.00, 1.33, 1.67, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose"
            }, 
            {
                "description": "Subjects will be monitored throughout the study for Adverse Events", 
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "17 days"
            }
        ], 
        "source": "Verisfield UK Ltd. Greek Branch", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Verisfield UK Ltd. Greek Branch", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}